<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112328</url>
  </required_header>
  <id_info>
    <org_study_id>2008-185-1153</org_study_id>
    <nct_id>NCT05112328</nct_id>
  </id_info>
  <brief_title>The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding</brief_title>
  <acronym>PREZENT</acronym>
  <official_title>The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding: Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the effect of high-dose pancreatic enzyme supplementation on nutritional indicators&#xD;
      and clinical course in critically ill patients undergoing enteral nutrition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Phase angle (°)</measure>
    <time_frame>Baseline, 7 days after starting enteral nutrition, 14 days after starting enteral nutrition</time_frame>
    <description>Change from Baseline Phase angle (°) at 2 weeks or discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skeletal Muscle Mass (SMM) (kg)</measure>
    <time_frame>Baseline, 7 days after starting enteral nutrition, 14 days after starting enteral nutrition</time_frame>
    <description>Skeletal Muscle Mass (SMM) (kg)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Critically Ill</condition>
  <condition>Enteral Feeding</condition>
  <condition>Exocrine Pancreatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exocrine Pacancreatic enzyme(Norzyme Capsule 40000 capsules) after meals 3 times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo after meals 3 times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exocrine Pancreatic Enzyme</intervention_name>
    <description>Pancreatic enzyme supplementation for critically ill patients on enteral nutrition</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Norzyme</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of Pancreatic enzyme for critically ill patients on enteral nutrition</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults 19 years and older&#xD;
&#xD;
          -  Hospitalized in the surgical/medical intensive care unit of the Seoul National&#xD;
             University Hospital&#xD;
&#xD;
          -  Enteral nutrition&#xD;
&#xD;
          -  Patients who consented to this study&#xD;
&#xD;
          -  Patients with risk factors for pancreatic exocrine dysfunction&#xD;
&#xD;
               -  Shock (Norepinephrine)&#xD;
&#xD;
               -  Sepsis (3 rd definition of sepsis)&#xD;
&#xD;
               -  Diabetes&#xD;
&#xD;
               -  Cardiac arrest&#xD;
&#xD;
               -  hyperlactatemia serum lactate &gt; 2 mmol/L)&#xD;
&#xD;
               -  Mechanical ventilation&#xD;
&#xD;
               -  Continuous renal replacement therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic pancreatitis&#xD;
&#xD;
          -  unresectable pancreatic cancer&#xD;
&#xD;
          -  History of pancreatectomy&#xD;
&#xD;
          -  Underlying diseases in which the effect of Exocrine pancreatic enzyme administration&#xD;
             is difficult to show&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
               -  Short bowel syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oh</last_name>
    <phone>+82-2-2072-3538</phone>
    <email>faun1226@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seoul National University Hospital</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Seung-Young Oh</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

